88915-34-8

Basic information

• Product Name: 4-PiperidinaMine, 3-Methyl-1-(phenylMethyl)-, (3R,4S)
• Synonyms: 4-PiperidinaMine, 3-Methyl-1-(phenylMethyl)-, (3R,4S);cis-3-Methyl-1-(phenylmethyl)-4-piperidinamine
• CAS NO: 88915-34-8
• Molecular Formula: C13H20N2
• Molecular Weight: 204
• Mol File: 88915-34-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.004
• CAS DataBase Reference: 4-PiperidinaMine, 3-Methyl-1-(phenylMethyl)-, (3R,4S)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PiperidinaMine, 3-Methyl-1-(phenylMethyl)-, (3R,4S)(88915-34-8)
• EPA Substance Registry System: 4-PiperidinaMine, 3-Methyl-1-(phenylMethyl)-, (3R,4S)(88915-34-8)

Safety Data

• Hazardous Substances Data: 88915-34-8(Hazardous Substances Data)

Upstream product

• 34737-89-8 1-Benzyl-3-methyl-4-piperidon 
• 790667-50-4 trans-1-benzyl-3-methylpiperidin-4-ol 
• 863249-31-4 (3S,4S)-3-methylpiperidin-4-yl pivalate 
• 100-52-7 benzaldehyde 
• 790667-50-4 (3R,4R)-1-benzyl-3-methylpiperidin-4-ol 
• 309912-49-0 (3S,4R)-1-benzyl-4-(N,N-dibenzylamino)-3-methylpiperidin-2-one 
• 213134-97-5 (3R,4S)-1-benzyl-4-(N,N-dibenzylamino)-3-methylpiperidin-2-one 
• 620165-90-4 (3R,4S)-4-Amino-1-benzyl-3-methyl-piperidin-2-one 

Relevant articles and documents

Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment

Recruitment of suppressive CD4+ FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents. Human Treg express CCR4 and can be recruited to the TME through the CC chemokine ligands CCL17 and CCL22. In some cancers, Treg accumulation correlates with poor patient prognosis. Preclinical data suggests that preventing the recruitment of Treg and increasing the population of activated effector T cells (Teff) in the TME can potentiate antitumor immune responses. We developed a novel series of potent, orally bioavailable small molecule antagonists of CCR4. From this series, several compounds exhibited high potency in distinct functional assays in addition to good in vitro and in vivo ADME properties. The design, synthesis, and SAR of this series and confirmation of its in vivo activity are reported.

CONDENSED PYRIDINE COMPOUND

The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).

CCR8 INHIBITORS

Disclosed are CCR8 inhibitors represented by Structural Formulas (I). The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.